TMCnet News
Pixium Vision Receives Clinical Trial Approval From UK Regulatory Authority for 150 Electrode IRIS®II Bionic Vision SystemPixium Vision (Paris:PIX) (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, today announced that it has received approval from the Medicines & Healthcare products Regulatory Agency (MHRA) in the UK to initiate a clinical trial for patients who have lost sight due to retinitis pigmentosa (RP) with the IRIS® II bionic vision system. This system being evaluated includes a mini bio-inspired camera and a 150 electrode epi-retinal implant with an explantable design. Participation of Moorfields Eye Hospital NHS Foundation Trust broadens the clinical study centres of excellence in addition to sites across France, Germany and Austria. Moorfields Eye Hospital is the oldest and largest centre for ophthalmic treatment, teaching and research in Europe. Additional clinical centres across Europe enables broader patient outreach, increased opportunity to participate in the clinical trial, and paves the way for future commercialisation of the bionic vision system. In parallel, Pixium Vision initiated last December CE mark approval process on the basis of IRIS clinical experience. Subject to CE mark approval timing, commercialisation is expected to start in H2 2016. Mahi Muqit, PhD FRCOphth, Consultant Ophthalmologist and Vitreoretinal Surgeon at Moorfields Eye Hospital, study Principal Investigator (UK) said, "We are excited to participate in the clinical trial of IRIS®II and be the first site in the UK. Patients with RP can now benefit from a new choice of retinal implant that may potentially further improve visual outcomes. This new clinical trial is key for ophthalmic reference centres like Moorfields to evaluate the latest technologies, and provide patients with a retinal implant that is differentiated and allows retinal implant exchanges in the future. We are delighted to work ith Pixium Vision to develop solutions for retinal dystrophies like RP and age-related macular degeneration (AMD (News - Alert))ý." Commenting on the announcement, Khalid Ishaque, CEO of Pixium Vision said, "The UK approval for the clinical study further reinforces our confidence in the IRIS®II platform, our first innovative bionic vision system." Khalid Ishaque added: "Currently as the only company developing an epi-retinal system for RP patients and a sub-retinal wireless photovoltaic implant for AMD patients, we are delighted to initiate this clinical partnership with the world renowned Moorfields Eye Hospital in the UK." IRIS® II epi-retinal system incorporates innovative features being evaluated, including:
About Moorfields Eye Hospital - www.moorfields.nhs.uk. About the IRIS® II clinical study - http://www.pixium-vision.com/en/media/press-releases About Pixium Vision - www.pixium-vision.com The company is EN ISO 13485 certified. Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including the Institut de la Vision in Paris, the Hansen Experimental Physics Laboratory at Stanford University, and Moorfields Eye Hospital in London.
Pixium Vision is listed on Euronext (Compartiment C) in Paris. IRIS® is a trademark of Pixium-Vision SA Disclaimer - http://www.pixium-vision.com/en/media/press-releases
View source version on businesswire.com: http://www.businesswire.com/news/home/20160531005551/en/ |
